NSE · Healthcare · Drug Manufacturers - Specialty & Generic
| Document | Date |
|---|---|
| Investor presentation · Q1 FY27 BALAXI PHARMACEUTICALS LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 • Q1 F | 2026-08-06 |
| Quarterly results · Q1 FY27 BALAXI PHARMACEUTICALS LIMITED – Q1 FY2026-27 SUMMARY HEADLINE NUMBERS STANDALONE RESULTS (Q1 FY2026-27) • Revenue from operations: Rs 1,558.37 lakh | 2026-08-05 |
| Annual report FY2026 BALAXI PHARMACEUTICALS LIMITED – FY 2025-26 SUMMARY HEADLINE NUMBERS • Consolidated revenue: ₹270.17 crore • Gross margin: 44.2% • Registered produc | 2026-07-31 |
| Quarterly results | 2026-07-14 |
| Investor presentation · Q4 FY26 BALAXI PHARMACEUTICALS LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • FY26 Consolidated Revenue: ₹270.17 crore (down 7.7% YoY from ₹292.56 crore in F | 2026-05-29 |
| Quarterly results · Q4 FY26 BALAXI PHARMACEUTICALS LIMITED – FINANCIAL SUMMARY Board Meeting Outcome | May 28, 2026 --- HEADLINE NUMBERS • Standalone Revenue (FY 2025-26): Rs | 2026-05-28 |
| Investor presentation BALAXI PHARMACEUTICALS LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • Q3 FY26 Revenue: ₹72.54 crore (1% YoY decline from ₹73.29 crore in Q3 FY25; 29% | 2026-01-29 |
| Quarterly results · Q3 FY26 BALAXI PHARMACEUTICALS LIMITED – DOCUMENT SUMMARY Q3 FY2025-26 Results & Board Meeting (28 January 2026) --- HEADLINE NUMBERS • Standalone Q3 Reven | 2026-01-28 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for BALAXI PHARMACEUTICALS LIMITED — free to start.
Google PlayApp StoreData updated 2026-09-18.